AVEO

AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma

AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC

AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q1 2021 Results - Earnings Call Transcript

AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021

AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors

AVEO Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares